Atopic dermatitis is a chronic relapsing skin condition associated with dry skin and itching. It is characterized by acute flare-ups of pruritic lesions over dry skin. Atopic dermatitis is a subset of the broad classification of eczema. It is the most common skin disease in children, with 50% of patients experiencing onset of disease within their 1st year of life and 85% before the age of 5.

For questions, please contact Liis Shea, Program Director, at lshea@icer.org.

Interventions of Interest:

  • abrocitinib (Pfizer)
  • tralokinumab (LEO Pharma)
  • baricitinib (Olumiant®, Eli Lilly, Incyte Corporation)
  • upadacitinib (Rinvoq®, AbbVie)
  • ruxolitinib (Incyte Corporation)

View the Key Stakeholder List.